AU784226B2 - Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix - Google Patents

Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix Download PDF

Info

Publication number
AU784226B2
AU784226B2 AU29255/01A AU2925501A AU784226B2 AU 784226 B2 AU784226 B2 AU 784226B2 AU 29255/01 A AU29255/01 A AU 29255/01A AU 2925501 A AU2925501 A AU 2925501A AU 784226 B2 AU784226 B2 AU 784226B2
Authority
AU
Australia
Prior art keywords
peptide
release
polymer
poly
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU29255/01A
Other languages
English (en)
Other versions
AU2925501A (en
Inventor
Joachim B. Kohn
Deborah M. Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of AU2925501A publication Critical patent/AU2925501A/en
Application granted granted Critical
Publication of AU784226B2 publication Critical patent/AU784226B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU29255/01A 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix Expired AU784226B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US60/174137 1999-12-31
PCT/US2001/000030 WO2001049249A2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Publications (2)

Publication Number Publication Date
AU2925501A AU2925501A (en) 2001-07-16
AU784226B2 true AU784226B2 (en) 2006-02-23

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29255/01A Expired AU784226B2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Country Status (5)

Country Link
EP (1) EP1263453A4 (https=)
JP (1) JP2003519164A (https=)
AU (1) AU784226B2 (https=)
CA (1) CA2396037A1 (https=)
WO (1) WO2001049249A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326425B2 (en) 1999-12-31 2008-02-05 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
EP2114298B1 (en) 2006-02-08 2022-10-19 Medtronic, Inc. Temporarily stiffened mesh prostheses
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
MX2009004821A (es) 2006-11-06 2009-11-23 Tyrx Pharma Inc Bolsas de malla para dispositivos medicos implantables.
AU2008232682B2 (en) 2007-03-29 2013-03-21 Medtronic, Inc. Biodegradable, polymer coverings for breast implants
MX2009011785A (es) 2007-05-02 2010-03-04 Tyrx Pharma Inc Polimeros de dihidroxibenzoato y usos de los mismos.
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8652525B2 (en) 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2737769C (en) 2008-09-22 2014-02-04 Medtronic, Inc. Linear polyesteramides from aminophenolic esters
EP2437724B1 (en) * 2009-06-01 2015-09-30 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
WO2011014859A1 (en) * 2009-07-31 2011-02-03 Rutgers, The State University Of New Jersey Biocompatible polymers for medical devices
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
JP6031033B2 (ja) 2010-08-25 2016-11-24 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． 医療デバイスの新規なコーティング
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011326417A1 (en) 2010-11-12 2013-05-09 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
AU2012283875B2 (en) 2011-07-20 2016-05-12 Medtronic, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
WO2015069305A1 (en) 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
EP3177319A1 (en) * 2014-08-04 2017-06-14 Janssen Sciences Ireland UC Compacted solid dosage form
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
US6120491A (en) * 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine
MXPA99007662A (es) * 1997-02-18 2002-07-22 Univ Rutgers Monomeros derivados de hidroxiacidos, y polimeros preparados a partir de los mismos.
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
ZA9811377B (en) * 1997-12-12 1999-08-27 Expression Genetics Inc Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
EP1073688B1 (en) * 1998-04-13 2015-03-04 Rutgers, The State University The construction of copolymer libraries
JP2002536695A (ja) * 1999-02-05 2002-10-29 エイリアン・テクノロジイ・コーポレーション アセンブリを形成するための装置および方法

Also Published As

Publication number Publication date
JP2003519164A (ja) 2003-06-17
WO2001049249A2 (en) 2001-07-12
AU2925501A (en) 2001-07-16
EP1263453A2 (en) 2002-12-11
WO2001049249A3 (en) 2002-01-17
EP1263453A4 (en) 2008-02-20
CA2396037A1 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
AU784226B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
US7521061B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
AU775905B2 (en) Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
AU600723B2 (en) Biodegradable microspheres as a carrier for macromolecules
Chiu et al. Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system
Tabata et al. Controlled delivery systems for proteins using polyanhydride microspheres
Ulbrich et al. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release
CA2213368C (en) Polyetherester copolymers as drug delivery matrices
US6589548B1 (en) Controlled drug delivery system using the conjugation of drug to biodegradable polyester
Ranade Drug delivery systems: 3A. Role of polymers in drug delivery
Tatykhanova et al. Ophthalmic drug delivery system based on the complex of gellan and ofloxacin
CA3086992C (en) Starting material for bulk drug or additives for drug, and bulk drug or drug using same
Gautier et al. Poly (L-lysine citramide), a water-soluble bioresorbable carrier for drug delivery: Aqueous solution properties of hydrophobized derivatives
Sparer Controlled release of drugs from glycosaminoglycan drug complexes
Gwon et al. New route for synthesizing poly (ethylene glycol)-acrylic acid hydrogels using γ-irradiation for drug delivery carriers
WO2014102741A2 (en) Pharmaceutical dosage form
WO2001036515A2 (en) Polymeric compositions and a method of making the same
US8709481B2 (en) System for controlled release of an active principle and method for preparation
Ye et al. The properties of polyesteramide and the effects on the stability of bovine serum albumin
CA1297627C (en) Biologically degradable polymers for depot preparations havingcontrolled release of the active compound
Rypáček et al. Self-Degradable Hydrogel with Covalently Bound Proteolytic Enzyme
Singh Smart polymer-based controlled-release drug-delivery systems for peptide and protein
Markland Modified polypeptides and polypeptide hydrogels for controlled drug delivery
Shieh Erosion and release from biodegradable polyanhydrides
WO2008152669A2 (en) Colloidal vectors with polyaminoacid structure for oral release of peptides and proteins and method for their production

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired